[HTML][HTML] Targeting HER2-positive breast cancer: advances and future directions

SM Swain, M Shastry, E Hamilton - Nature reviews Drug discovery, 2023 - nature.com
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

[HTML][HTML] Advances in dendritic cell vaccination therapy of cancer

S Najafi, K Mortezaee - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Traditionally, vaccines have helped eradication of several infectious diseases and also
saved millions of lives in the human history. Those prophylactic vaccines have acted through …

[HTML][HTML] Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy

D Qian, J Li, M Huang, Q Cui, X Liu, K Sun - Biomedicine & …, 2023 - Elsevier
Breast cancer (BC) is the most common cancer in women worldwide. Although substantial
progress has been made in the diagnosis and treatment of breast cancer, the efficacy and …

Theranostic chimeric antigen receptor (CAR)-T cells: Insight into recent trends and challenges in solid tumors

K Kheyrolahzadeh, MR Tohidkia, A Tarighatnia… - Life Sciences, 2023 - Elsevier
Cell therapy has reached significant milestones in various life-threatening diseases,
including cancer. Cell therapy using fluorescent and radiolabeled chimeric antigen receptor …

[HTML][HTML] Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer

M Kundu, R Butti, VK Panda, D Malhotra, S Das… - Molecular Cancer, 2024 - Springer
Breast cancer, the most frequent female malignancy, is often curable when detected at an
early stage. The treatment of metastatic breast cancer is more challenging and may be …

[HTML][HTML] Dendritic cells in cancer immunology and immunotherapy

L Hato, A Vizcay, I Eguren, JL Pérez-Gracia… - Cancers, 2024 - mdpi.com
Simple Summary Although immune check point inhibitors have been established as a new
paradigm in cancer treatment, they have shown no clinical benefit in immune excluded or …

[HTML][HTML] The Potential of Dendritic Cell Subsets in the Development of Personalized Immunotherapy for Cancer Treatment

AV Gorodilova, KV Kitaeva, IY Filin… - Current issues in …, 2023 - mdpi.com
Since the discovery of dendritic cells (DCs) in 1973 by Ralph Steinman, a tremendous
amount of knowledge regarding these innate immunity cells has been accumulating. Their …

Application of Engineered Dendritic Cell Vaccines in Cancer Immunotherapy: Challenges and Opportunities

P Li, L Jia, X Bian, S Tan - Current Treatment Options in Oncology, 2023 - Springer
Opinion statement The primary objective of this study is to evaluate the effectiveness of
cancer vaccines containing genetically modified dendritic cells (DCs) in inducing …

[HTML][HTML] Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment …

W Becker, PB Olkhanud, N Seishima… - … for ImmunoTherapy of …, 2024 - ncbi.nlm.nih.gov
Background Despite advances in checkpoint inhibitor (CPI) therapy for cancer treatment,
many cancers remain resistant. Tumors deemed “cold” based on lack of T cell infiltration …